{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T19:33:03Z","timestamp":1772307183447,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"S7","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Syst Biol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12918-017-0513-2","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T08:54:39Z","timestamp":1513846479000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Constraint-based perturbation analysis with cluster Newton method: a case study of personalized parameter estimations with irinotecan whole-body physiologically based pharmacokinetic model"],"prefix":"10.1186","volume":"11","author":[{"given":"Shun","family":"Asami","sequence":"first","affiliation":[]},{"given":"Daisuke","family":"Kiga","sequence":"additional","affiliation":[]},{"given":"Akihiko","family":"Konagaya","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2017,12,21]]},"reference":[{"issue":"1","key":"513_CR1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","volume":"32","author":"M Hay","year":"2014","unstructured":"Hay M, Thomas DW, Craighead JL, et al. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32(1):40\u201351.","journal-title":"Nat Biotechnol"},{"issue":"10","key":"513_CR2","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.mayocp.2012.07.007","volume":"87","author":"S Mustaqeem","year":"2012","unstructured":"Mustaqeem S, Vincent Rajkumar S. The high cost of cancer drugs and what we can do about it. Mayo Clin Proc. 2012;87(10):935\u201343.","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"513_CR3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.clcc.2012.05.004","volume":"11","author":"O Capitain","year":"2012","unstructured":"Capitain O, Asevoaia A, Boisdron-Celle M, et al. Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. Clin Colorectal Cancer. 2012;11(4):263\u20137.","journal-title":"Clin Colorectal Cancer"},{"issue":"4","key":"513_CR4","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.3892\/or.2016.4575","volume":"35","author":"IS Vizirianakis","year":"2016","unstructured":"Vizirianakis IS, Mystridis GA, Avgoustakis K, et al. Enabling personalized cancer medicine decisions: the challenging pharmacological approach of PBPK models for nanomedicine and pharmacogenomics (review). Oncol Rep. 2016;35(4):1891\u2013904.","journal-title":"Oncol Rep"},{"issue":"2","key":"513_CR5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/clpt.2010.298","volume":"89","author":"P Zhao","year":"2011","unstructured":"Zhao P, Zhang L, Grillo JA, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther. 2011;89(2):259\u201367.","journal-title":"Clin Pharmacol Ther"},{"key":"513_CR6","unstructured":"US Food and Drug Administration (FDA) \u201cGuidance for Industry, Drug Interaction Studies \u2013 Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations, DRAFT GUIDANCE,\u201d Feb, 2012."},{"key":"513_CR7","unstructured":"European Medicine Agency (EMA) \u201cGuideline on the investigation of drug interactions,\u201d Jan, 2013."},{"key":"513_CR8","unstructured":"IMBRUVICATM (ibrutinib) capsules, package insert (US FDA)."},{"key":"513_CR9","unstructured":"CERDELGA (eliglustat) capsules, package insert (US FDA)."},{"key":"513_CR10","unstructured":"Aoki Y, Hayami K, Sterc HD, et al. Cluster Newton Method for Sampling Multiple. Solutions of an Underdetermined Inverse Problem: Parameter Identification for Pharmacokinetics. NII Technical Reports. 2011;"},{"issue":"Suppl 3","key":"513_CR11","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/1752-0509-7-S3-S3","volume":"7","author":"K Yoshida","year":"2013","unstructured":"Yoshida K, Maeda K, Kusuhara H, et al. Estimation of feasible solution space using cluster Newton method: application to pharmacokinetic analysis of irinotecan with physiologically-based pharmacokinetic models. BMC Syst Biol Suppl. 2013;7(Suppl 3):S3.","journal-title":"BMC Syst Biol Suppl"},{"issue":"2","key":"513_CR12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.tiv.2005.06.045","volume":"20","author":"NF Smith","year":"2006","unstructured":"Smith NF, Figg WD, Sparreboom A. Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol in Vitro. 2006;20(2):163\u201375.","journal-title":"Toxicol in Vitro"},{"issue":"16","key":"513_CR13","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1200\/JCO.2008.20.6300","volume":"27","author":"F Innocenti","year":"2009","unstructured":"Innocenti F, Kroetz DL, Schuetz E, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol. 2009;27(16):2604\u201314.","journal-title":"J Clin Oncol"},{"issue":"9","key":"513_CR14","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1517\/17425255.4.9.1143","volume":"4","author":"AN Edginton","year":"2008","unstructured":"Edginton AN, Theil FP, Schmitt W, et al. Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol. 2008;4(9):1143\u201352.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"513_CR15","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10928-007-9053-5","volume":"34","author":"S Willmann","year":"2007","unstructured":"Willmann S, H\u00f6hn K, Edginton A, et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn. 2007;34(3):401\u201331.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"513_CR16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0090-9556(24)15060-X","volume":"28","author":"JG Slatter","year":"2000","unstructured":"Slatter JG, Schaaf LJ, Sams JP, et al. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. Infusion of [(14)C]CPT-11 in cancer patients. Drug Metab Dispos. 2000;28(4):423\u201333.","journal-title":"Drug Metab Dispos"},{"key":"513_CR17","unstructured":"International Commission on Radiological Protection (ICRP), \u201cBasic Anatomical and Physiological Data for Use in Radiological Protection: Reference Values,\u201d ICRP Publi- cation 89. Elsevier Science, Amsterdam, The Netherlands, 2002."},{"issue":"16","key":"513_CR18","first-page":"3752","volume":"56","author":"K Takasuna","year":"1996","unstructured":"Takasuna K, Hagiwara T, Hirohashi M, et al. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 1996;56(16):3752\u20137.","journal-title":"Cancer Res"},{"issue":"1","key":"513_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1137\/S1064827594276424","volume":"18","author":"L Shampine","year":"1997","unstructured":"Shampine L, Reichelt M. The matlab ode suite. SIAM J Sci Comput. 1997;18(1):1\u201322.","journal-title":"SIAM J Sci Comput"},{"issue":"2","key":"513_CR20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11095-015-1785-0","volume":"33","author":"K Fujita","year":"2016","unstructured":"Fujita K, Masuo Y, Okumura H, et al. Increased plasma concentrations of unbound SN-38, the active metabolite of irinotecan, in cancer patients with severe renal failure. Pharm Res. 2016;33(2):269\u201382.","journal-title":"Pharm Res"},{"issue":"1","key":"513_CR21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","volume":"57","author":"AA Mangoni","year":"2004","unstructured":"Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6\u201314.","journal-title":"Br J Clin Pharmacol"},{"key":"513_CR22","unstructured":"CAMPTOSAR (Irinotecan) Injection, package insert (US FDA)."},{"issue":"3","key":"513_CR23","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0009-9236(97)90166-1","volume":"61","author":"EA Sotaniemi","year":"1997","unstructured":"Sotaniemi EA, Arranto AJ, Pelkonen O, et al. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther. 1997;61(3):331\u20139.","journal-title":"Clin Pharmacol Ther"}],"container-title":["BMC Systems Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12918-017-0513-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T03:27:22Z","timestamp":1751167642000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcsystbiol.biomedcentral.com\/articles\/10.1186\/s12918-017-0513-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":23,"journal-issue":{"issue":"S7","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["513"],"URL":"https:\/\/doi.org\/10.1186\/s12918-017-0513-2","relation":{},"ISSN":["1752-0509"],"issn-type":[{"value":"1752-0509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"129"}}